Filings (90d)
Other insiders active in the same stocks
Insiders who reported open-market trades in the last 12 months at the companies KKR Genetic Disorder L.P. files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
- Neil Kumar - $45.20M in BBIO purchases and sales in the last 12 months
- Jennifer E. Cook - $21.92M in BBIO purchases and sales in the last 12 months
- Frank McCormick - $13.31M in BBIO purchases and sales in the last 12 months
- Andrew Lo - $6.32M in BBIO purchases and sales in the last 12 months
- Andrea Ellis - $5.65M in BBIO purchases and sales in the last 12 months
- Hannah Valantine - $4.37M in BBIO purchases and sales in the last 12 months
More insiders (A-Z)
Browse nearby insider profiles in alphabetical order.
Frequently asked questions
What is KKR Genetic Disorder L.P.?
KKR Genetic Disorder L.P. is an investment firm of BridgeBio Pharma, Inc. (BBIO). InsiderAlpha holds 1 primary Form 4 filing for it, the earliest from 2025, updated as new SEC EDGAR filings are processed.
When did KKR Genetic Disorder L.P. last file a Form 4?
The only primary Form 4 on record is dated 12 May 2025.
Has KKR Genetic Disorder L.P. been buying or selling stock?
Recorded transactions: 0 open-market purchases and 1 open-market sale ($205.20M) across all tracked filings.
